SCHEMBL2089284

SCHEMBL2089284

[O]Cc1nc(-c2ccccc2)no1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.68
RAB9A P51151 8/20 0.64
NPC1 O15118 6/20 0.64
L3MBTL1 Q9Y468 4/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2C19 P33261 1/20 0.64
MAPT P10636 3/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
ALDH1A1 P00352 3/20 0.60
MAPK1 P28482 3/20 0.60
TDP1 Q9NUW8 3/20 0.60
TSHR P16473 3/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CYP2D6 P10635 1/20 0.58
KCNH2 Q12809 1/20 0.58
NR1H4 Q96RI1 1/20 0.57
HTR1A P08908 1/20 0.55
HRH3 Q9Y5N1 1/20 0.55
S1PR1 P21453 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094888 0.81 NOTUM (0.70) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL7977071 0.81 NOTUM (0.68) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL12477652 0.81 NOTUM (0.69) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL91541 0.81 NOTUM (0.68) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL17595755 0.81 NOTUM (1.00) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL28869608 0.81 NOTUM (0.68) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL655414 0.81 NOTUM (0.68) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL4611029 0.80 ALDH1A1 (0.68) NOTUMRAB9ANPC1L3MBTL1CYP1A2
SCHEMBL96695 0.80 RAB9A (0.68) RAB9ANPC1L3MBTL1MAPTSMN1; SMN2
SCHEMBL7598545 0.79 S1PR1 (0.81) NOTUMRAB9ANPC1L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NOTUM 4043/4885RAB9A 3153/4885NPC1 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.